Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
NCT ID: NCT04912024
Last Updated: 2022-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
458 participants
OBSERVATIONAL
2021-05-15
2022-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
EXtension of Tablo TrEatmeNt Duration Registry
NCT04912050
The EvAluation of TaBlo In-CLinic and In-HOme
NCT02460263
Modalities of Renal Replacement Therapy in Pediatric Acute Kidney Injury
NCT01569698
Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure
NCT00280072
High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease
NCT03456232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tablo Hemodialysis System
Participants who were prescribed acute intermittent renal replacement therapy on the Tablo Hemodialysis System at a dialysate flow rate of 300 mL/min
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
Conventional Hemodialysis System
Participants who were prescribed acute intermittent renal replacement therapy on conventional hemodialysis systems (Non-Tablo) with dialysate flow rates of ≥ 500 mL/min
Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System
Intermittent renal replacement therapy using the Tablo Hemodialysis System in the acute setting for participants with AKI or ESKD
Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Intermittent renal replacement therapy using Conventional Hemodialysis Systems in the acute setting for participants with AKI or ESKD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant weighs ≥ 34kg.
* Participant was hospitalized and had dialysis dependent End-Stage Renal Disease or Acute Kidney Injury and was prescribed acute intermittent renal replacement therapy.
Exclusion Criteria
* Any documented condition the Physician feels would prevent the participant from successful inclusion in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Outset Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Adventist Health System
Orlando, Florida, United States
Texas Health Harris Methodist Hospital Fort Worth
Fort Worth, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.